Torrent Pharmaceuticals (Torrent) today announced that it has entered into a non-exclusive patent licensing agreement with Takeda to commercialize Vonoprazan in India. Vonoprozan is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of acid related disorders - Gastroesophageal Reflux Disease (GERD). Torrent will market Vonoprazan under its own trademark, Kabvie. As per a 2019 study published by Indian Journal of Gastroenterology prevalence of GERD in Indian population is around 8.2%, with a higher prevalence of around 11.1% in urban population. According to AWACS MAT April 2024 data, the Indian market for treatments used in GERD is valued at INR 8,064 crore, growing at 8% CAGR over the last 4 years. Currently treatments such as Pantoprazole (Proton Pump Inhibitors) are used to treat GERD. Availability of P-CABs such as Kabvie will make accessible new and effective treatments of GERD for the Indian population.Powered by Capital Market - Live News

Torrent Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 24 May 2024, inter alia, have recommended the final dividend of Rs 6 per equity Share (i.e. 120%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Torrent Pharmaceuticals rose 56.45% to Rs 449.00 crore in the quarter ended March 2024 as against Rs 287.00 crore during the previous quarter ended March 2023. Sales rose 9.91% to Rs 2695.00 crore in the quarter ended March 2024 as against Rs 2452.00 crore during the previous quarter ended March 2023.For the full year,net profit rose 33.01% to Rs 1656.00 crore in the year ended March 2024 as against Rs 1245.00 crore during the previous year ended March 2023. Sales rose 11.60% to Rs 10562.00 crore in the year ended March 2024 as against Rs 9464.00 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales2695.002452.00 10 10562.009464.00 12 OPM %32.7629.65 -31.8930.03 - PBDT834.00629.00 33 3072.002554.00 20 PBT631.00433.00 46 2264.001847.00 23 NP449.00287.00 56 1656.001245.00 33 Powered by Capital Market - Live News

The Board of Torrent Pharmaceuticals at its meeting held on 24 May 2024 has approved issuance of equity shares including convertible bonds / debentures through Qualified Institutional Placement (QIP) and or any other modes for an amount not exceeding Rs 5,000 crore. Powered by Capital Market - Live News

Torrent Pharmaceuticals has fixed 21 June 2024 as record date for final dividend for the year 2023-24, if declared. Powered by Capital Market - Live News